

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisal

## Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171)

## Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Celgene (lenalidomide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Equalities National Council</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Age</li> <li>• Independent Cancer Patients Voice</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia CARE</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Myeloma UK</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Haematology</li> <li>• Cancer Network Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Accord (doxorubicin)</li> <li>• Actavis (doxorubicin)</li> <li>• Aspen (melphalan)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Genus Pharmaceuticals (vincristine)</li> <li>• Hameln Pharmaceuticals (dexamethasone)</li> <li>• Hospira UK (dexamethasone, doxorubicin, vincristine)</li> <li>• Janssen-Cilag (bortezomib)</li> <li>• Medac GmbH (doxorubicin)</li> <li>• Merck, Sharp and Dohme (dexamethasone)</li> <li>• Napp Pharmaceuticals (bendamustine)</li> <li>• Pfizer (cyclophosphamide, doxorubicin, )</li> <li>• Rosemount Pharmaceuticals (dexamethasone)</li> <li>• Teva UK (vincristine)</li> <li>• Wockhardt UK (doxorubicin)</li> </ul> <p><u>Relevant research groups</u></p>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Health Forum</li> <li>• UK Myeloma Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Leeds South and East CCG</li> <li>• NHS Telford &amp; Wrekin CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• Elimination of Leukaemia Fund</li> <li>• Health Research Authority</li> <li>• Leukaemia and Lymphoma Research</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Research Institute of the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• TBC</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

#### PTO for definitions of commentators and consultees

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.